Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial

Clinical Research in Cardiology

Volumn 100, Issue 7, 2011, Pages 571-577

  Biteker, Murat ^a   Duran, Nilüfer Ekşi ^b   Kaya, Hasan ^b   Gündüz, Sabahattin ^b   Tanboǧa, Halil Ibrahim ^b   Gökdeniz, Tayyar ^b   Kahveci, Gökhan ^b   Akgün, Taylan ^b   Yildiz, Mustafa ^b   Özkan, Mehmet ^b  

^a HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b Ko uyolu Kartal Heart Education and Research Hospital   (Turkey)

Author keywords

Levosimendan; Peripartum cardiomyopathy; Treatment

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LEVOSIMENDAN; LOOP DIURETIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; DEMOGRAPHY; DRUG DOSE TITRATION; DRUG EFFICACY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT ATRIUM; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HUMAN; PERIPARTUM CARDIOMYOPATHY; PREDICTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVOR; TREATMENT OUTCOME;

ADULT; CARDIOMYOPATHIES; CARDIOVASCULAR AGENTS; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; FEMALE; HEART VENTRICLES; HUMANS; HYDRAZONES; PERIPARTUM PERIOD; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PYRIDAZINES; TREATMENT OUTCOME; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 80051784214     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-010-0279-7     Document Type: Article

References (22)

1. Demakis JG, Rahimtoola SH (1971) Peripartum cardiomyopathy. Circulation 44:964-968
2. Sliwa K, Mocumbi AO (2010) Forgetten cardiovascular diseases in Africa. Clin Res Cardiol 99:65-74
3. Pearson GD, Veille JC, Rahimtoola S et al (2000) Peripartum cardiomyopathy: National heart, lung and blood institute and office of rare diseases (national institutes of health) workshop recommendations and review. JAMA 283:1088-1183
4. Hilfiker-Kleiner D, Kaminski K, Podewski E et al (2007) A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128:589-600 (Pubitemid 46206082)
5. Lehmann A, Boldt J, Kirchner J (2003) The role of Ca-sensitizers for the treatment of heart failure. Curr Opin Crit Care 9:337-344 (Pubitemid 37204787)
6. Hitz MP, Bertram H, Köditz H (2008) Levosimendan for bridging in a pediatric patient with Alström syndrome awaiting heart-lung transplantation. Clin Res Cardiol 97:846-848
7. Follath F, Cleland JG, Just H et al (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised doubleblind trial. Lancet 360:196-202 (Pubitemid 34804646)
8. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, RUSSLAN Study Investigators (2002) Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebocontrolled, double-blind study (RUSSLAN). Eur Heart J 23: 1422-1432 (Pubitemid 36285574)
9. Mebazaa A, Nieminen MS, Packer M, SURVIVE Investigators et al (2007) Levosimendan vs. dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 297:1883-1891 (Pubitemid 46707842)
10. De Luca L, Colucci WS, Nieminen MS, Massie BM, Gheorghiade M (2006) Evidence-based use of levosimendan in different clinical settings. Eur Heart J 27(16):1908-1920 (Pubitemid 44297362)
11. Benlolo S, Lefoll C, Katchatouryan V, Payen D, Mebazaa A (2004) Successful use of levosimendan in a patient with peripartum cardiomyopathy. Anesth Analg 98:822-824 (Pubitemid 38252683)
12. Nguyen HD, McKeown B (2005) Levosimendan for post-partum cardiomyopathy. Crit Care Resusc 7:107-110
13. Benezet-Mazuecos J, de la Hera J (2008) Peripartum cardiomyopathy: a new successful setting for levosimendan. Int J Cardiol 123(3):346-347 (Pubitemid 350302020)
14. Gottdiener JS, Bednarz J, Devereux R, American Society of Echocardiography et al (2004) American society of echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr 17:1086-1119
15. Midei MG, DeMent SH, Feldman AM, Hutchins GM, Baughman KL (1990) Peripartum myocarditis and cardiomyopathy. Circulation 81:922-928 (Pubitemid 20090390)
16. Bozkurt B, Villaneuva FS, Holubkov R et al (1999) Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol 34:177-180
17. Biteker M, Duran NE, Ozkan M (2009) The role of bromocriptine in peripartum cardiomyopathy. Am J Obstet Gynecol 201(2):e13
18. Sliwa K, Blauwet L, Tibazarwa K et al (2010) Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy. A proof-of-concept pilot study. Circulation 121(13):1465-1473
19. Sliwa K, Hilfiker-Kleiner D, Petrie MC et al (2010) Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the heart failure association of the European society of cardiology working group on peripartum cardiomyopathy. Eur J Heart Fail 12(8):767-778
20. Duran N, Günes H, Duran I, Biteker M, Ozkan M (2008) Predictors of prognosis in patients with peripartum cardiomyopathy. Int J Gynaecol Obstet 101:137-140
21. O'Connell JB, Costanzo-Nordin MR, Subramanian R et al (1986) Peripartum cardiomyopathy: clinical, hemodynamic, histologic and prognostic characteristics. J Am Coll Cardiol 8:52-56 (Pubitemid 16094113)
22. Amos AM, Jaber WA, Russell SD (2006) Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J 152:509-513 (Pubitemid 44233417)